MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2023 International Congress

    motor and non-motor correlates of hyposmia detected by the italian olfactory identification test (ioit) in an italian cohort of parkinson’s disease patients

    A. Mechelli, N. Tambasco, M. Filidei, C. Maremmani, M. Pierini, P. Nigro, S. Simoni, L. Parnetti (Catanzaro, Italy)

    Objective: To characterize olfaction in a cohort of PD patients and to investigate the relationship between olfactory impairment with both motor and non-motor features and other clinical characteristics…
  • 2023 International Congress

    Cortical excitability of sensorimotor cortex in Parkinson’s disease-related pain

    MK. Lu, CM. Chen, SM. Liu, CH. Tsai (Taichung, Taiwan)

    Objective: To clarify the functional role of sensorimotor cortex in Parkinson’s disease (PD)-related pain. Background: Pain is one of the most common nonmotor symptoms in…
  • 2023 International Congress

    Primary CNS Lymphoma presenting with Hemichorea Hemiballismus.

    N. Sharma (Chandigarh, India)

    Objective: Completing the list of Hemichorea Hemiballismus apart from stroke and hyperglycaemic states. Background: 61years old female presented with subacute onset abnormal irregular purposeless movements…
  • 2023 International Congress

    Lysosomal-driven reduction of alpha-synuclein aggregates in a neuron-like model of Parkinson’s disease

    S. Lucas-Del-Pozo, G. Uras, F. Fierli, AHV. Schapira (London, United Kingdom)

    Objective: To test whether PIKfyve inhibition results in a lysosomal-driven reduction of alpha-synuclein aggregates in a mutant neuroblastoma cell line overexpressing an aggregation-prone form of…
  • 2023 International Congress

    AAV5-miHTT gene therapy mediates sustained mutant huntingtin lowering in brain and cerebrospinal fluid of Huntington’s disease minipigs up to 5 years

    L. Van_der Bent, C. Brouwers, A. Stam, L. Spronck, J. Klíma, J. Juhásová, B. Levinská, S. Juhás, J. Motlík, M. Evers, Z. Ellederova, A. Valles (Amsterdam, Netherlands)

    Objective: Our objective is to assess long-term safety of and durability of an adeno-associated viral vector serotype 5 encoding an engineered miRNA (AAV5-miHTT) targeting human…
  • 2023 International Congress

    Innovating Clinical Trial Design to Accelerate Assessment of Disease-Modifying Treatments for Parkinson’s: The EJS ACT-PD Initiative

    G. Mills, R. Chapman, S. Collins, R. Ellis-Doyle, C. Gonzalez-Robles, M. Zeissler, O. Bandmann, R. Barker, J. Carpenter, J. Chataway, J. Duffen, S. Gandhi, K. Mcfarthing, S. Mullin, A. Schapira, A. Schrag, C. Carroll, T. Foltynie (London, United Kingdom)

    Objective: To design an optimal multi-arm, multi-stage (MAMS) platform trial for disease-modifying therapies (DMTs) in Parkinson’s disease (PD). Background: The current clinical trials process cannot…
  • 2023 International Congress

    Age at Onset and Therapeutic Efficacy of Primidone in Essential Tremor Patients

    F. Jamal, G. Jackson, A. Sarwar, P. Mandava (Houston, USA)

    Objective: To study the therapeutic response of primidone in different age groups of Essential Tremor (ET) patients, based on age at onset. Background: Essential Tremor…
  • 2023 International Congress

    Design of a time-to-event study in GBA Parkinson’s Disease patients: Efficacy and safety of BIA 28-6156, an allosteric activator of beta-glucocerobridase (GCase)

    L. Magalhães, M. Fonseca, G. Castilla-Fernández, R. Costa, D. Simon, J. Holenz, N. Mendonça (Coronado, Portugal)

    Objective: To assess the efficacy of BIA 28-6156 in delaying clinically meaningful motor progression in PD patients who have a PD-risk associated variant in the…
  • 2023 International Congress

    Speech difficulties and dopaminergic neurodegeneration in Parkinson’s Disease

    S. Polychronis, B. Ribba, G. Nasios, E. Dardiotis, G. Pagano (Ioannina, Greece)

    Objective: To evaluate the association between speech difficulties and neurodegeneration of the putaminal dopaminergic system in people with early-stage treated with symptomatic therapy and advanced-stage…
  • 2023 International Congress

    Disorder of bulk lipid transfer? Lipid composition and distribution in cellular models of VPS13A disease

    K. Peikert, A. Spranger, E. Fischer, H. Glaß, B. Falkenburger, G. Miltenberger-Miltenyi, D. Tyteca, C. Klose, D. Grossmann, A. Hermann (Rostock, Germany)

    Objective: To study the overall lipid composition and distribution in red blood cells (RBCs) and neurons derived from VPS13A disease patients, a neurodegenerative disorder associated…
  • « Previous Page
  • 1
  • …
  • 41
  • 42
  • 43
  • 44
  • 45
  • …
  • 186
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • To be or not to bupropion: a drug-induced parkinsonism?
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
      • Help & Support
      • About Us
      • Cookies & Privacy
      • Wiley Job Network
      • Terms & Conditions
      • Advertisers & Agents
      Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
      Wiley